-

Bruker Launches X4 POSEIDON™ Advanced X-Ray Microscope for Three-Dimensional Microscopy in Industrial and Scientific Applications

KONTICH, Belgium--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research.

The X4 POSEIDON features a high-end X-ray source that improves 3D resolution more than an order of magnitude compared to similar instruments. The system offers a large field-of-view high-efficiency detector, which optionally can be combined with a high-resolution scientific CMOS detector for multi-vision analytical flexibility.

The X4 POSEIDON is powered by 3DxSUITE software, with automated protocols, an intuitive and customizable user interface, integrated database and user management, and multi-language support. Designed for low maintenance, the system enhances uptime and reduces cost of ownership. Options are field-upgradable, allowing for cost-effective expansion to meet evolving analytical needs and future innovations.

Diederik Ellerbroek, Bruker AXS Vice President for Materials Science XRM, stated: “The X4 POSEIDON represents a significant advancement in benchtop XRM design and performance. It offers flexibility and performance for fast 3D high-resolution XRM with a large field of view for industrial and materials science research applications in the geosciences, pharmaceutical R&D and QA/QC, composite materials, batteries, renewable energy, and microelectronics.”

Guillaume Tetard, Bruker Biospin Vice President for Optical and mCT Preclinical Imaging, added: “The X4 POSEIDON is a cutting-edge XRM system with unmatched image quality in its category for performance across life-science applications from bone and dental research, to soft tissue imaging, plant and animal biology.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI and HPC. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:
Joseph Kostka
Director - Investor Relations
Bruker Corporation
T: +1 978 313-5773
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Joseph Kostka
Director - Investor Relations
Bruker Corporation
T: +1 978 313-5773
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A sli...

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

BREMEN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search...

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...
Back to Newsroom